Ocuphire Pharma Investor Day Presentation Deck

P 93 VEGA-1: Improvement in Functional Near Vision Nyxol Single Drop Significantly Improves Functional Near Visual Acuity VEGA-1 Phase 2 Trial Percent of Subjects (%) 40% 35% 30% 25% 20% 15% 10% 5% 0% 0% 3% 20/15 Improvement in Snellen Equivalent 56% achieved 20/40 or better at 12 hours 0% 3% 12% 20/20 0% Binocular DCNVA Nyxol Alone 20/25 16% 0% 22% 20/32 0% 36% 20/40 Snellen Acuity Baseline 12 Hours Baseline Inclusion: Photopic DCNVA of 20/50 or worse 23% 34% Source: VEGA-1 TLR Table 14.2.24.1 Percent of Subjects with Photopic DCNVA by Time Point (PP Population) 15% 19% 5% 20/50 20/63 20/80 11% 0% 20/100 Nyxol achieved 20/40 vision at 12 Hours Ocuphire PHARMA

View entire presentation